Searchable abstracts of presentations at key conferences on calcified tissues

ba0003oc1.2 | Phosphate metabolism, fracture repair and osteoarthritis | ECTS2014

Study of Hyp or Phex null male fetuses reveals that eightfold increased FGF23 does not alter fetal–placental phosphorus homeostasis or prenatal bone formation and mineralization

Ma Yue , Kirby Beth J. , Kovacs Christopher S.

Fibroblast growth factor-23 (FGF23) controls serum phosphorus by acting on the kidneys to excrete phosphorus and reduce calcitriol. These actions are well established in adults and children, but whether FGF23 regulates fetal phosphorus metabolism is unknown. We used X-linked Hyp or Phex null male fetuses to study the effect of excess FGF23 on fetal phosphorus metabolism. Phex+/− females and WT males were mated to generate WT, Phe...

ba0001pp129 | Calciotropic and phosphotropic hormones and mineral metabolism | ECTS2013

The Ellsworth-Howard test revisited

Tang J C Y , Washbourne C J , Galitzer H , Hiemstra T , Meek C , Chipchase A , Fraser W D

Background: Pseudohypoparathyroidism (PHP) is a group of heterogeneous endocrine disorders characterised by hormone resistance, primarily to parathyroid hormone (PTH). The resistance is caused by defects in the GNAS gene, which encodes the Gsα protein that activates the cAMP pathway. PHP patients demonstrate elevated plasma PTH, hypocalcaemia, hyperphosphataemia with normal renal function. PTH resistance can be confirmed by Ellsworth-Howard test (PTH s...

ba0005p407 | Osteoporosis: treatment | ECTS2016

Impact of 3-year vitamin D and calcium supplementation on mineral and organic matrix formation of trabecular bone in postmenopausal osteoporosis

Paschalis E P , Gamsjaeger S , Hassler N , Fahrleitner-Pammer A , Dobnig H , Stepan J J , Eriksen E F , Klaushofer K

Clinical trials involving drug therapies for postmenopausal osteoporosis typically compare effects of the active drug combined with vitamin D (vit D) and calcium (Ca) vs vit D and Ca supplementation on its own. Bone strength is estimated based on the amount of bone, frequently expressed as bone mineral density determined by dual X-ray absorptiometry, and quality of bone, hardly measured in clinical practice.The purpose of the present study was to compare...

ba0003pp354 | Osteoporosis: treatment | ECTS2014

Denosumab treatment in women with osteoporosis reduces hip cortical porosity

Zebaze Roger M , Libanati Cesar , McClung Michael R , Zanchetta Jose R , Kendler David L , Hoiseth Arne , Wang Andrea , Ghasem-Zadeh Ali , Seeman Ego

Bone strength is influenced by cortical thickness, area, mass and porosity, all of which contribute to nonvertebral fracture risk. Cortical porosity is one parameter of structural decay associated with bone fragility. This is caused by unbalanced and accelerated remodelling of Haversian units which enlarge, coalesce and fragment the cortex. Antiresorptive therapies will limit progression of cortical porosity; reducing existing porosity would be a goal for those already at incr...

ba0003pp336 | Osteoporosis: treatment | ECTS2014

The effect of alendronate oral jelly in the treatment of osteoporosis in clinical settings

Okimoto Nobukazu , Arita Shinobu , Akahoshi Syojiro , Yoshioka Toru , Fuse Yoshifumi

Alendronate is one of the most popular anti-resorptive drugs and widely used to treat osteoporotic patients in the world. In Japan, alendronate oral jelly (ALN-J) as a new formulation was launched in 2013. Dissolution test and bioequivalence study were performed between ALN-J and alendronate oral weekly tablet (ALN-T), and bioequivalence of both drugs was approved. Dosage and administration of ALN-J is the same as ALN-T. Moreover, ALN-J has special features of easy swallowing ...

ba0001oc2.5 | Bone quality and fracture repair - animal models | ECTS2013

Glucagon-like peptide 1 receptor is required for optimal bone strength and quality

Mieczkowska Aleksandra , Irwin Nigel , Flatt Peter R , Chappard Daniel , Mabilleau Guillaume

Objectives: Glucagon-like peptide 1 is secreted by intestinal L-cells into the blood supply in response to nutrients in the intestine. Although osteoblasts express the GLP-1 receptor (GLP-1R), the main action of the GLP-1/GLP-1R pathway in bone physiology and bone quality is unknown. The aim of the present study was to investigate bone strength and quality in a mouse model of GLP-1R deficiency.Materials/methods: Eight 16 weeks-old GLP-1R knock-out male m...

ba0001pp39 | Bone biomechanics and quality | ECTS2013

Glucose-dependent insulinotropic polypeptide receptor deletion results in a reduced bone strength and quality

Mieczkowska Aleksandra , Irwin Nigel , Flatt Peter R , Chappard Daniel , Mabilleau Guillaume

Objectives: Glucose-dependent insulinotropic polypeptide (GIP) is secreted by intestinal K-cells into the blood supply in response to nutrient ingestion and absorption. Although osteoblasts and osteoclasts express the GIP receptor (GIPR), the main action of the GIP/GIPR pathway in bone physiology and bone quality is unknown. The aim of the present study was to investigate bone quality in a mouse model of GIPR deficiency.Materials/methods: Eleven 16 weeks...

ba0001pp102 | Calciotropic and phosphotropic hormones and mineral metabolism | ECTS2013

A genetic polymorphism of osteocalcin is associated with BMI but not with parameters of glucose and lipid metabolism in women with polycystic ovary syndrome

Schwetz Verena , Trummer Olivia , Giuliani Albrecht , Pieber Thomas R , Obermayer-Pietsch Barbara , Lerchbaum Elisabeth

Introduction: Osteocalcin (OC) is a marker of bone formation but also seems to play a hormonal role in the regulation of glucose and energy metabolism. Recently, an association of BMI with a haplotype composed of three single nucleotide polymorphisms (SNPs) in the gene for OC, located on chromosome 1q22, was observed in ethnically homogeneous European pedigrees.Aim: The aim of the study was to test the association of these three polymorphisms in the gene...